Elicio shares tumble after pancreatic cancer therapy misses mid-stage study goal
Elicio Therapeutics shares dropped roughly 73% after its pancreatic cancer therapy failed to significantly extend the time patients lived without disease recurrence in a mid-stage study. The setback is particularly damaging given the company had already flagged a limited cash runway of approximately $15 million through Q4 2026. Elicio said it is evaluating strategic financing and operational options in the wake of the failure.
The Atomic take
A 73% wipeout on a missed disease-free survival endpoint leaves Elicio with roughly $15 million to fund a turnaround, a runway that now looks dangerously thin for advancing its lymph-node-targeting cancer vaccine platform. The "strategic financing and operational options" language is corporate code for dilution, asset sales, or a fire-sale acquisition, and any of those will determine whether the technology survives even if the company doesn't. Watch for terms of any near-term capital raise and whether management salvages the program's KRAS-targeting approach in a different indication.
Read the full story at Reuters →Know where humanity is headed.
Five forces. One brief. Free, every Monday morning.
Get The Atomic Five